Of the nine estimates for the June quarter, eight have been increased in the past 30 days, while nine of 11 estimates have gone up for the full year in the same time period.
In contrast, none of Pfizer 's (nyse: PFE - news - people ) top eight drugs in the third quarter were introduced in the past three years, even though they accounted for most of the New York-based drug giant's sales.